Displaying all 2 publications

Abstract:
Sort:
  1. A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder
    Bose R, Hamdani SU, Minhas FA, Herr KJ
    Curr Med Res Opin, 2022 Jan 20.
    PMID: 35049384 DOI: 10.1080/03007995.2022.2031146
    OBJECTIVE: To evaluate the effectiveness of vortioxetine in major depressive disorder (MDD) when used as a first-line versus second-line treatment or later.

    METHODS: This was a post-hoc analysis of three 3-month non-interventional, prospective studies of vortioxetine in MDD - REVIDA (Malaysia, Philippines, Singapore, Thailand), PREVIDA (Pakistan) and TREVIDA (Taiwan). Improvements in depressive symptoms (PHQ-9, CGI-S), cognitive function (PDQ-D) and work productivity (WPAI) were compared between studies, and in a pooled analysis of patients using vortioxetine as first line versus second-line treatment or later. Safety was compared between studies.

    RESULTS: Overall, 798 patients were analyzed (PREVIDA =425, REVIDA =130, TREVIDA =243). Most patients in PREVIDA (60.5%)/REVIDA (57.4%) used vortioxetine as first-line treatment versus TREVIDA (21.8%). Generally, greater improvements from baseline were observed across outcome measures in PREVIDA/REVIDA versus TREVIDA (Month 3, p 

  2. Fulltext Cyclodextrin nanoparticles in targeted cancer theranostics
    Bose R, Jayawant M, Raut R, Lakkakula J, Roy A, Alghamdi S, et al.
    Front Pharmacol, 2023;14:1218867.
    PMID: 37601050 DOI: 10.3389/fphar.2023.1218867
    The field of cancer nanotheranostics is rapidly evolving, with cyclodextrin (CD)-based nanoparticles emerging as a promising tool. CDs, serving as nanocarriers, have higher adaptability and demonstrate immense potential in delivering powerful anti-cancer drugs, leading to promising and specific therapeutic outcomes for combating various types of cancer. The unique characteristics of CDs, combined with innovative nanocomplex creation techniques such as encapsulation, enable the development of potential theranostic treatments. The review here focuses mainly on the different techniques administered for effective nanotheranostics applications of CD-associated complex compounds in the domain of cancer treatments. The experimentations on various loaded drugs and their complex conjugates with CDs prove effective in in vivo results. Various cancers can have potential nanotheranostics cures using CDs as nanoparticles along with a highly efficient process of nanocomplex development and a drug delivery system. In conclusion, nanotheranostics holds immense potential for targeted drug delivery and improved therapeutic outcomes, offering a promising avenue for revolutionizing cancer treatments through continuous research and innovative approaches.
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links